ProSomnus Inc. (OSAP)
| Market Cap | 8.18M |
| Revenue (ttm) | 27.65M |
| Net Income (ttm) | -24.10M |
| Shares Out | 16.18M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,677 |
| Open | 0.163 |
| Previous Close | 0.170 |
| Day's Range | 0.150 - 0.170 |
| 52-Week Range | 0.100 - 0.300 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OSAP
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California. [Read more]
Financial Performance
In 2023, ProSomnus's revenue was $27.65 million, an increase of 42.59% compared to the previous year's $19.39 million. Losses were -$24.10 million, 237.2% more than in 2022.
Financial numbers in USD Financial StatementsNews
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial result...
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the ...
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study f...
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-pos...
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the thi...
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter fina...
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
PLEASANTON, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announces ma...
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakeven Company will leverage new capital inflow to optimiz...
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices for the Treatment of Obstructive Sleep Apnea...
ICR Hosts ProSomnus CEO Len Liptak on the Welcome to the Arena Podcast
NEW YORK--(BUSINESS WIRE)---- $OSA #IR--ICR, a leading strategic communications and advisory firm, is pleased to announce that Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus, Inc. (NA...
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), tod...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second quar...
Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of three ...
Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the present...
ProSomnus Reports First Quarter 2023 Financial Results
PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (...
Study to be Presented at European Respiratory Society and European Sleep Research Society's Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
Study data indicates that ProSomnus precision oral appliances appear to be more efficacious than traditional oral appliances for the treatment of mild, moderate, and severe Obstructive Sleep Apnea Stu...
ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company's Novel Precision Sleep Apnea Medical Devices
PLEASANTON, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
PLEASANTON, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company's Novel Precision Sleep Apnea Medical Devices
PLEASANTON, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will ...
ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society's Sleep and Breathing 2023 Conference
PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023
SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announ...
ProSomnus® Appoints Brian Dow as Chief Financial Officer
PLEASANTON, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
Company commences execution of strategic growth initiatives following Initial Public Offering Company commences execution of strategic growth initiatives following Initial Public Offering